PHASEBIO PHARMACEUTICALS, INC. INDEMNIFICATION AGREEMENTIndemnification Agreement • October 5th, 2018 • PhaseBio Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
Contract Type FiledOctober 5th, 2018 Company Industry JurisdictionThis INDEMNIFICATION AGREEMENT (this “Agreement”) is dated as of , 20 and is between PHASEBIO PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and (“Indemnitee”).
PhaseBio Pharmaceuticals, Inc. [•] Shares Common Stock ($0.001 par value) Underwriting AgreementUnderwriting Agreement • October 5th, 2018 • PhaseBio Pharmaceuticals Inc • Pharmaceutical preparations • New York
Contract Type FiledOctober 5th, 2018 Company Industry JurisdictionPhaseBio Pharmaceuticals, Inc., a corporation organized under the laws of Delaware (the “Issuer”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom Citigroup Global Markets Inc., Cowen and Company, LLC and Stifel, Nicolaus & Company, Incorporated (the “Representatives”) are acting as representatives, [•] shares of common stock, $0.001 par value per share(“Common Stock”) of the Issuer (said shares to be issued and sold by the Issuer being hereinafter called the “Underwritten Securities”). The Issuer also proposes to grant to the Underwriters an option to purchase up to [•] additional shares of Common Stock to cover over-allotments, if any (the “Option Securities;” the Option Securities, together with the Underwritten Securities, hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the t